To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicef 300 mg Capsule Fasting Conditions

This study has been completed.
Information provided by:
Sandoz Identifier:
First received: April 15, 2009
Last updated: December 30, 2009
Last verified: April 2009
To demonstrate the relative bioequivalence of Cefdinir and Omnicel 300 mg capsule fasting conditions.

Condition Intervention Phase
Drug: Cefdinir 300 mg Capsule (Sandoz, Austria)
Drug: Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Single Center, Open, Randomized, 2-Way, 2-Period, 2-Sequence Crossover Study of the Bioequivalence of 300 mg Cefdinir (Test Formulation) and Omnicel 300 mg Capsule (Reference Formulation) Each Given as a Single Oral Dose to Twenty-Eight Healthy Male and/or Female Volunteers in the Fasting State

Resource links provided by NLM:

Further study details as provided by Sandoz:

Primary Outcome Measures:
  • Bioequivalence based on AUC and Cmax [ Time Frame: 14 days ] [ Designated as safety issue: Yes ]

Enrollment: 28
Study Start Date: April 2005
Study Completion Date: April 2005
Primary Completion Date: April 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Cefdinir 300 mg Capsule (Sandoz, Austria)
Drug: Cefdinir 300 mg Capsule (Sandoz, Austria)
Active Comparator: 2
Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)
Drug: Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)


Ages Eligible for Study:   18 Years to 56 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria:

  • Positive test results for HIV or hepatitis B or C.
  • Treatment for drug or alcohol dependence.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00882700

Sponsors and Collaborators
Sandoz Inc.
Principal Investigator: Richard Larouche, M.D. SFBC Anapharm
  More Information

Responsible Party: Eric Mittleberg, Ph.D, VP of Product Development, Sandoz Inc. Identifier: NCT00882700     History of Changes
Other Study ID Numbers: 50038 
Study First Received: April 15, 2009
Last Updated: December 30, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by Sandoz:

Additional relevant MeSH terms:
Anti-Bacterial Agents
Anti-Infective Agents processed this record on May 26, 2016